Viruses, 2023 Despite the benefits of combinatorial antiretroviral therapies (cART), virotoxic HIV proteins are still detectable within the central nervous system. Approximately half of all cART-treated patients contend with neurological impairments.
Emaya M. Moss +3 more
doaj +2 more sources
Structure, 2008 NBD-556 is a class of HIV-1 entry inhibitors that binds HIV-1 surface glycoprotein gp120 and induces conformational changes, which mimic those caused by CD4 binding. Here, Madani et al. (2008) show that NBD-556 binds to the highly conserved "Phe-43 cavity" on gp120.
Repik, Alexander, Clapham, Paul R.
openaire +4 more sources
Insight derived from molecular dynamics simulations into molecular motions, thermodynamics and kinetics of HIV-1 gp120. [PDF]
PLoS ONE, 2014 Although the crystal structures of the HIV-1 gp120 core bound and pre-bound by CD4 are known, the details of dynamics involved in conformational equilibrium and transition in relation to gp120 function have remained elusive.
Peng Sang +4 more
doaj +1 more source
HIV-1 gp120 induces expression of IL-6 through a nuclear factor-kappa B-dependent mechanism: suppression by gp120 specific small interfering RNA. [PDF]
PLoS ONE, 2011 In addition to its role in virus entry, HIV-1 gp120 has also been implicated in HIV-associated neurocognitive disorders. However, the mechanism(s) responsible for gp120-mediated neuroinflammation remain undefined.
Ankit Shah +11 more
doaj +1 more source
The glycan shield of HIV is predominantly oligomannose independently of production system or viral clade. [PDF]
PLoS ONE, 2011 The N-linked oligomannose glycans of HIV gp120 are a target for both microbicide and vaccine design. The extent of cross-clade conservation of HIV oligomannose glycans is therefore a critical consideration for the development of HIV prophylaxes.
Camille Bonomelli +7 more
doaj +1 more source
A strategy for eliciting antibodies against cryptic, conserved, conformationally dependent epitopes of HIV envelope glycoprotein. [PDF]
PLoS ONE, 2010 Novel strategies are needed for the elicitation of broadly neutralizing antibodies to the HIV envelope glycoprotein, gp120. Experimental evidence suggests that combinations of antibodies that are broadly neutralizing in vitro may protect against ...
Hanna C Kelker +2 more
doaj +1 more source
Synergistic cooperation between methamphetamine and HIV-1 gsp120 through the P13K/Akt pathway induces IL-6 but not IL-8 expression in astrocytes. [PDF]
PLoS ONE, 2012 HIV-1 envelope protein gp120 has been extensively studied for neurotoxic effects that have been attributed to the increased expression of various proinflammatory cytokines in the CNS.
Ankit Shah +4 more
doaj +1 more source
Neurobiology of Disease, 2010 HIV-1 effects on the blood–brain barrier (BBB) structure and function are still poorly understood in animal models based on direct administration of recombinant HIV proteins.
Jean-Pierre Louboutin +5 more
doaj +1 more source
A Chimeric HIV-1 gp120 Fused with Vaccinia Virus 14K (A27) Protein as an HIV Immunogen. [PDF]
PLoS ONE, 2015 In the HIV vaccine field, there is a need to produce highly immunogenic forms of the Env protein with the capacity to trigger broad B and T-cell responses.
Aneesh Vijayan +8 more
doaj +1 more source
Frontiers in Neuroscience, 2021 Human immunodeficiency virus envelope glycoprotein 120 (gp120) leads to hyperalgesia. Long non-coding RNAs are characterized by the lack of a protein-coding sequence and may contribute to the development and maintenance of inflammatory and ...
Lichao Peng +20 more
doaj +1 more source